[CAS NO. 9004-66-4] Iron dextran

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [9004-66-4]

Catalog

HY-107928

Brand

MCE

CAS

9004-66-4

DESCRIPTION [9004-66-4]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Iron dextran]

For research use only. We do not sell to patients.

Summary

Iron dextran (Fe dextran) can be used in the study of iron-deficiency anemia in animals ^[1] ^[2] .

In Vivo

Iron dextran (FeDex, IP, 4 weeks, 300 μL of 10 mg) treatment does not increase NSR iron but causes iron-trapping in the tetinal vasculature ^[1] .
Four weeks of IP FeDex injection in 2-month-old WT mice leads to iron accumulation in the RPE and rVECs, but did not increase NSR iron or induce photoreceptor degeneration ^[1] .

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wild-type (WT) and RS- Hepc KO mice ^[1] .
Dosage:	IP.
Administration:	300 μL of 10 mg daily for 5 days each week for 2 or 4 weeks.
Result:	Markedly elevated iron levels in 2 and 4 weeks of FeDex-injection groups, by 365.4-fold and 405.4-fold, respectively, compared with PBS controls.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03279536	Woman´s Health University Hospital, Egypt	Iron Deficiency Anemia	November 1, 2017	Phase 1\|Phase 2
NCT00704028	American Regent, Inc.	Anemia	June 2008	Phase 3
NCT01307007	American Regent, Inc.	Iron Deficiency Anemia	September 2010	Phase 2
NCT05714176	Menoufia University\|Tanta University	CKD - Chronic Kidney Disease	February 1, 2023	Phase 4
NCT02731378	Shanghai East Hospital	Chemotherapy-induced Anaemia	December 2016	Phase 4
NCT05340465	University of Washington\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Prematurity\|Iron-deficiency\|Iron Deficiency Anemia\|Iron Malabsorption	November 27, 2022	Phase 2
NCT05167734	Mayo Clinic\|National Heart, Lung, and Blood Institute (NHLBI)	Anemia\|Critical Illness	November 30, 2021	Phase 2
NCT01290315	American Regent, Inc.	Iron Deficiency Anemia	August 2009	Phase 2
NCT05047211	The University of Texas Medical Branch, Galveston	Anemia, Iron Deficiency\|Delivery Complication	October 7, 2021	Phase 4
NCT00482716	St. Bartholomew´s Hospital\|National Cancer Institute (NCI)	Anemia\|Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Unspecified Adult Solid Tumor, Protocol Specific	January 2007	Phase 3
NCT00401544	Amgen	Anemia\|Non-Myeloid Malignancies	December 2006	Phase 2
NCT03212781	Assiut University	Anemia	June 2016	Phase 3
NCT05960227	Hospital Civil de Guadalajara	Anemia, Iron Deficiency\|Acute Kidney Injury	January 6, 2023	Phase 2
NCT03438227	Indiana University	Iron Deficiency Anemia of Pregnancy\|Iron Malabsorption	April 15, 2018	Phase 4
NCT00593619	London Health Sciences Centre	Iron Deficiency Anemia\|Perioperative Blood Conservation	January 2008	Phase 4
NCT02086838	Ain Shams University	Treatment of Iron Deficiency Anemia in Pregnancy	July 2013	Phase 4

Appearance

Liquid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

H ₂ O : ≥ 50 mg/mL

* "≥" means soluble, but saturation unknown.